Search clinical trials for: zetia

Total 73 results

NYU Langone Health
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Cholesterol Lowering and Residual Risk in Diabetes, Type 1 (CHORD1)

Type 1 Diabetes

United States
Mayo Clinic

Recruiting

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

Hepatitis C | Heart Transplant Infection | Kidney Transplant; Complications

United States
Organon and Co

Completed

A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)

Hypercholesterolemia
Organon and Co

Completed

Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)

Hypercholesterolemia
Organon and Co

Completed

An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)

Hypercholesterolemia
paresh Dandona

Terminated

Anti-inflammatory Effects of Simvastatin

Inflammation | Atherosclerosis | Hypercholesterolemia

United States
Baylor College of Medicine
Merck Sharp & Dohme LLC

Completed

Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome. (Merck-123)

Metabolic Syndrome

United States
NYU Langone Health

Completed

CHOlesterol Lowering and Residual Risk in Type 2 Diabetes (CHORD)

Type 2 Diabetes

United States
Amgen

Completed

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 (MENDEL-2)

Hyperlipidemia

United States, Denmark, Taiwan, Korea, Republic of, Australia, Belgium, Canada, South Africa, France, Turkey
Amgen

Completed

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 (LAPLACE-2)

Hyperlipidemia

United States, Denmark, France, Italy, Czechia, Taiwan, Switzerland, Korea, Republic of, Germany, Hong Kong, Netherlands, Australia, Belgium, Canada, Hungary, South Africa, Russian Federation, Spain, United Kingdom, Sweden, Mexico
Amgen

Completed

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels (MENDEL)

Hyperlipidemia

United States, Denmark, Australia, Belgium, Canada
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects (GAUSS)

Hyperlipidemia

United States, Denmark, Australia, Belgium, Spain, Finland, Sweden, Canada
VA Office of Research and Development

Terminated

Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C

Chronic Hepatitis C

United States
Amarin Pharma Inc.

Completed

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL (MARINE)

Hypertriglyceridemia

United States, Netherlands, Russian Federation, Ukraine, Denmark, Finland, Germany, India, Italy, Mexico, South Africa
Amarin Pharma Inc.

Completed

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) (ANCHOR)

Hypertriglyceridemia

United States
Amarin Pharma Inc.

Completed

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin (REDUCE-IT)

Cardiovascular Diseases

United States, Australia, Canada, India, Netherlands, New Zealand, Poland, Romania, Russian Federation, South Africa, Ukraine
Organon and Co
Schering-Plough

Completed

MD Ezetimibe Cyclosporine Interaction (0653-057)

Cholesterol
Organon and Co

Completed

Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)

Hypercholesterolemia
Organon and Co

Completed

Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED)

Lipid Metabolism Disorder
Organon and Co

Completed

Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)

Cardiovascular Disorder
Organon and Co

Completed

Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)

Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)

Atherosclerosis | Hypercholesterolemia
Organon and Co
Merck Frosst Canada Ltd.

Terminated

Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)

Atherosclerosis | Hypercholesterolemia
Organon and Co

Completed

A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)

Hypercholesterolemia
Organon and Co

Completed

Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)

Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)

Atherosclerosis | Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)

Atherosclerosis | Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)

Coronary Artery Disease | Atherosclerosis | Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)

Atherosclerosis | Hypercholesterolaemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578) (ENHANCE)

Atherosclerosis | Hypercholesterolemia | Hyperlipoproteinemia Type II
Organon and Co

Completed

Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)

Hypercholesterolemia | Coronary Heart Disease
Organon and Co
Bayer

Completed

A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)

Hypercholesterolemia | Familial Hypercholesterolemia | Homozygous Sitosterolemia
Organon and Co
Merck Sharp & Dohme LLC

Completed

Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)

Primary Hypercholesterolemia
Organon and Co

Completed

A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)

Hyperlipidemia
Organon and Co
Merck Sharp & Dohme LLC

Terminated

Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)

Coronary Artery Disease | Atherosclerosis | Hypercholesterolemia
Organon and Co
Bayer

Completed

A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)

Hypercholesterolemia | Familial Hypercholesterolemia | Homozygous Sitosterolemia
Organon and Co

Completed

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)

Hypercholesterolemia
Organon and Co

Completed

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)

Hypercholesterolemia
UCSF Benioff Children's Hospital Oakland
Merck Schering-Plough

Completed

Effects of Ezetimibe on the Absorption of Oxidized Cholesterol

Hypercholesterolemia

United States
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4 (GAUSS-4)

Hypercholesterolemia

Japan
Medical College of Wisconsin

Completed

Effect of Diabetes Mellitus on Cholesterol Metabolism

Type 2 Diabetes Mellitus | Hypercholesterolemia | Type 1 Diabetes Mellitus

United States
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 (GAUSS-2)

Hyperlipidemia

United States, Denmark, Belgium, Germany, Hong Kong, Netherlands, France, Australia, Canada, South Africa, United Kingdom, Spain, Poland, Switzerland
University of California, San Diego

Completed

Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis

Non Alcoholic Steatohepatitis

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

Hypercholesterolemia

United States, France, Italy, Israel, United Kingdom, Austria, Canada, Norway
Esperion Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

Atherosclerosis | Hypercholesterolemia | Statin Adverse Reaction

United States
Esperion Therapeutics, Inc.

Completed

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Diabetes Mellitus, Type 2 | Diabetes | Cholesterolemia

United States
Esperion Therapeutics, Inc.

Completed

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

Hyperlipidemias

United States
Esperion Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Hypercholesterolemia

United States
Baylor College of Medicine
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

Peripheral Arterial Disease

United States
LMC Diabetes & Endocrinology Ltd.
Bausch Health Americas, Inc.

Completed

Randomized Trial Comparing Colesevelam vs. Ezetimibe (GOAL-RCT)

Type 2 Diabetes Mellitus

Canada

3

Subscribe